Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Second-Line Setting. [PDF]
Fakhri B +6 more
europepmc +1 more source
The BMX Tyrosine Kinase : A Signal Mediator in Hematopoietic and Endothelial/Epithelial Cells [PDF]
Ekman, Niklas
core
Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor. [PDF]
Salles G +14 more
europepmc +1 more source
Move along, nothing to see here: Btk inhibitors stop platelets sticking to plaques [PDF]
Busygina +5 more
core +1 more source
Response of renal cell carcinoma to ibrutinib, a bruton tyrosine kinase inhibitor, in a patient treated for chronic lymphocytic leukemia. [PDF]
Hosier GW, Touma NJ.
europepmc +1 more source
Challenges with Bruton’s Tyrosine Kinase Inhibitors Treatment
openaire +1 more source

